酒精戒断的长期结果
Giulio Sansone1,2, Pierre Megevand1, Serge Vulliémoz1
1Department of Clinical Neurosciences, University Hospital of Geneva & Faculty of Medicine, Geneva, Switzerland.
European journal of neurology
|October 12, 2023
概括
酒精戒断发作 (AWS) 可能会在11%的患者中复发,风险因素包括先前的AWS和头骨骨折. 这些发作增加了风险,并与明显更高的死亡率有关.
科学领域:
- 神经学 神经学
- 成 药物 药物 药物 药物
- 临床研究 临床研究
背景情况:
- 酒精戒断 (AWS) 是慢性酒精滥用的已知并发症.
- 关于AWS后的长期复发率和预后的知识有限.
研究的目的:
- 确定AWS复发的风险因素.
- 调查AWS后患者的长期结果.
主要方法:
- 在2013-2021年期间接受AWS治疗的199名患者的回顾性单中心研究.
- 分析了病史,药物使用 (二,ASM),实验室结果,EEG和CT发现.
- 研究的AWS复发到2022年4月.
主要成果:
- 11%的患者经历了AWS复发,平均时间为470.5天.
- 复发的危险因素包括以前的AWS,头骨骨折和形EEG异常.
- 死亡率为每年2.9%,是普通人群的13倍,风险因素是AWS病史和脑病性EEG.
结论:
- 延迟AWS复发发生在11%的患者中,与增加风险的因素有关.
- 复发和死亡的风险因素需要进一步的前性研究,以找到最佳的管理策略.
相关概念视频
CNS Depressants: Alcohol and Nicotine
221
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
221
Seizures: Classification
378
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
378
Antiepileptic Drugs: Potassium Channel Activators
192
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
192
Arteries of the Lower Limbs
194
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
194
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
Antiepileptic Drugs: GABAergic Pathway Potentiators
426
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
426


